Hong Kong market could open cash flood gates for U.S. biotechs

(Reuters) – When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *